Lead Product(s) : Tarumase
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SolasCure Gets FDA Fast Track for Aurase Wound Gel for Calciphylaxis Ulcers
Details : Aurase Wound Gel contains Tarumase, a clone of the key enzyme in maggot saliva that breaks down fibrin, elastin and collagen in wounds. It is being investigated for calciphylaxis ulcers.
Product Name : Aurase Wound Gel
Product Type : Enzyme
Upfront Cash : Inapplicable
June 16, 2025
Lead Product(s) : Tarumase
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Partnership
Teva UK and Closed Loop Medicine Announce Strategic Partnership for Personalised Medicines
Details : Teva will use Closed Loop Medicine’s SaMD platform for personalized chronic disorder treatments like CLM-HT01.
Product Name : CLM-HT01
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 26, 2024
Lead Product(s) : Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Vitaria
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LivaNova will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the potential for autonomic regulation therapy (ART) via vagus nerve stimulation to improve long-term cardiovascular function in patients with heart failure.
Product Name : Vitaria
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 08, 2020
Lead Product(s) : Vitaria
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : miRNA-125b
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The micro-RNA was identified as suitable for further development based on favorable pharmacokinetic results as well as pharmacodynamic data at the molecular level.
Product Name : miRNA-125b
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 31, 2020
Lead Product(s) : miRNA-125b
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable